Chronic Kidney Disease (CKD) is a worldwide epidemic and escalating problem. Approximately 20 million adults in the United States are in various stages of CKD, with ˃400, 000 individuals with end stage kidney disease and ˃300, 000 individuals requiring maintenance hemodialysis. Hypertension is the persistent elevation of arterial blood pressure in which DBP values ˃ 90 mmHg and SBP values ˃140mmHg. Serum uric acid is commonly elevated in subjects with chronic kidney diseases. The present review is aimed on to study the effect of Losartan and Cilnidipine on uric acid levels in CKD patients with hypertension. Losartan enhances the renal excretion of uric acid by increasing the urinary pH and also inhibits the URAT1 expressed in the brush-border membrane of the renal proximal tubule and thus prevents the reabsorption of uric acid. Cilnidipine increases the uric acid clearance by enhancing the glomerular filteration of uric acid.